[{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Artemisinin","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oncotelic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Oncotelic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Autotelic Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2-like dopamine receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncotelic Therapeutics \/ Oncotelic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Oncotelic Therapeutics \/ Oncotelic Therapeutics"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Autotelic Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2-like dopamine receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncotelic Therapeutics \/ Oncotelic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Oncotelic Therapeutics \/ Oncotelic Therapeutics"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OT-101","moa":"TGF beta-2 messenger RNA (TGFB2 mRNA)","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncotelic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oncotelic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"OT-101","moa":"TGF beta-2 messenger RNA (TGFB2 mRNA)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncotelic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OT-101","moa":"TGF beta-2 messenger RNA (TGFB2 mRNA)","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncotelic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||Transforming growth factor beta-2 mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncotelic Therapeutics \/ Oncotelic Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ Oncotelic Therapeutics"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Funding","leadProduct":"Trabedersen","moa":"||Transforming growth factor beta-2 mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncotelic Therapeutics \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncotelic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Sapu Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Trabedersen","moa":"Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncotelic Therapeutics \/ Sapu Bioscience","highestDevelopmentStatusID":"9","companyTruncated":"Oncotelic Therapeutics \/ Sapu Bioscience"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncotelic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oncotelic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Mosaic ImmunoEngineering","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Acquisition","leadProduct":"Trabedersen","moa":"Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Oncotelic Therapeutics \/ Mosaic ImmunoEngineering","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ Mosaic ImmunoEngineering"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncotelic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncotelic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Golden Mountain Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Agreement","leadProduct":"Trabedersen","moa":"Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncotelic Therapeutics \/ Golden Mountain Partners","highestDevelopmentStatusID":"9","companyTruncated":"Oncotelic Therapeutics \/ Golden Mountain Partners"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Trabedersen","moa":"Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncotelic Therapeutics \/ Mateon Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Oncotelic Therapeutics \/ Mateon Therapeutics"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Trabedersen","moa":"Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncotelic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Trabedersen","moa":"Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncotelic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Trabedersen","moa":"Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncotelic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncotelic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oncotelic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Dragon Overseas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Agreement","leadProduct":"Trabedersen","moa":"Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncotelic Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Oncotelic Therapeutics \/ Dragon Overseas","highestDevelopmentStatusID":"4","companyTruncated":"Oncotelic Therapeutics \/ Dragon Overseas"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Combretastatin A1 Diphosphate","moa":"Tubulin polymerisation","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncotelic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Oncotelic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Medicilon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncotelic Therapeutics \/ Oncotelic Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Oncotelic Therapeutics \/ Oncotelic Therapeutics"}]
Find Clinical Drug Pipeline Developments & Deals by Oncotelic Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target